// App-Quantinova.ai

2252 : Higher Matrix Metalloproteinase Levels Are Predictive of Incident Interstitial Lung Disease Among a Cohort of US Veterans with Rheumatoid Arthritis

Researchers

Presenter

  • Brent Luedders

Principal Investigators

  • Dana Ascherman

  • Joshua Baker

  • Michael Duryee

  • Yangyuna Yang

  • Punyasha Roul

  • Katherine Wysham

  • Paul Monach

  • Andreas Reimold

  • Gail Kerr

  • Gary Kunkel

  • Grant Cannon

  • Jill Poole

  • Geoffrey Thiele

  • Ted Mikuls

  • Bryant England

Medical Centers

  • University of Nebraska Medical Center, Omaha, NE

  • University of Pittsburgh, Pittsburgh, PA

  • University of Pennsylvania, Philadelphia, PA

  • UNMC, Omaha, NE.

  • VA-Puget Sound/University of Washington, Seattle, WA

  • VA Boston Healthcare System, Boston, MA

  • The University of Texas Southwestern Medical Center, Dallas, TX

  • Washington DC VA Medical Center, Georgetown and Howard Universities, Washington DC, DC

  • University of Utah, Salt Lake City, UT

  • Retired, Salt Lake City, UT

  • Division of Radiology, University of Nebraska Medical Center, Omaha, NE

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Pulmonary/Respiratory Diseases

Disease

  • Interstitial lung disease

  • Rheumatoid arthritis

  • Inflammatory Arthritis

Biomarkers

  • Matrix metalloproteinase 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multicenteric

  • Prospective

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved